AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00372437
Drug: MGCD0103
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MGCD0103 as an oral dose three times per week.
Trial: NCT03440359
Drug: Ovidrel 250 MCG Per 0.5 ML Prefilled Syringe
RxNorm normalized name: Ovidrel 250 MCG per 0.5 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ovidrel 250 mcg given when leading follicle size is \> 17 mm in diameter
Trial: NCT00910793
Drug: Inuvair
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 µg formoterol and 100 µg beclometasone dipropionate combination spray pMDI aerosol
Trial: NCT04041284
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT03464656
Drug: Fairhaven Pro for men
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fairhaven Pro for men~The antioxidant formula (Fairhaven Health) contains:~* B12 (1000 mcg)~* Zinc (30 mg)~* Selenium (140 mcg)~* Arginine (350 mg)~* L-carnitine tartrate (2000 mg) , providing 1,340 mg of L-carnitine~* CoQ10 (200 mg)~* Vitamin C (120 mg) and Vitamin E (200 IU)
Trial: NCT02246166
Drug: Test tablet
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The active tablet will be administered orally. Product administration will occur within 30mins of the baseline assessment of symptom severity
Trial: NCT01827631
Drug: GSK1605786 capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Swedish Orange, size 0, hard gelatine capsules
Trial: NCT01385735
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 Tbl per day, 12 week (84 days) duration
Trial: NCT03478111
Drug: CMAB008
FDA approved: no
EMA approved: no
PMDA approved: no
Description: the study drug
Trial: NCT02980224
Drug: OmegaD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OmegaD Softgels
Trial: NCT02980224
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Softgels
Trial: NCT02455401
Drug: High dose remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention: continuously intravenous infusion of remifentanil 0.1 mcg/kg/min after bolus injection of remifentanil 1.0 mcg/kg for 2 minutes
Trial: NCT02455401
Drug: Low dose remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention: continuously intravenous infusion of remifentanil 0.1 mcg/kg/min after bolus injection of remifentanil 0.5 mcg/kg for 2 minutes
Trial: NCT02455401
Drug: No remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention: no remifentanil will be administrated
Trial: NCT00189462
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01233622
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03769896
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: capsule, corn starch, daily basis
Trial: NCT01966666
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mL 0.9% sodium chloride.
Trial: NCT02320396
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets
Trial: NCT03977207
Drug: Levothyroxine Sodium
RxNorm normalized name: Levothyroxine Sodium
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Thyroid hormone supplement
Trial: NCT03977207
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral capsule
Trial: NCT02595723
Drug: Phenytoin 200 mg capsule
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Phenytoin oral capsule was initiated on Day 1 and administered at 200 mg twice/day for four consecutive days (Days 1 - 4).
Trial: NCT02595723
Drug: Phenytoin-matched Placebo capsule
RxNorm normalized name: phenytoin Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenytoin-matched oral Placebo capsule was initiated on Day 1 and administered for four consecutive days (Days 1 - 4).
Trial: NCT02535611
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beside the usual treatment of ischemic stroke, this group will receive placebo for 4 weeks.
Trial: NCT03051360
Drug: PCSK9 Inhibitor [EPC]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive PCSK9 inhibitor by a biweekly injection
Trial: NCT03051360
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive Placebo by a biweekly injection
Trial: NCT00000522
Drug: chlorthalidone
RxNorm normalized name: Chlorthalidone
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01441531
Drug: Placebo pill given one hour before surgery
RxNorm normalized name: Vitafol-One Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pill given
Trial: NCT02986594
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01925209
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo to BYM338 was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
Trial: NCT00996944
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects completing the screening period will be randomized (1:1) to receive the IR or placebo for 12 weeks. The treatment will be started at the initial dose of 0.25 mg/day within 1 to 3 hours before bedtime.
Trial: NCT03594227
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo - oral administration
Trial: NCT04622345
Drug: VSJ-110
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ophthalmic solution
Trial: NCT04622345
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ophthalmic solution
Trial: NCT04803500
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: single injection of simvastatin gel in the gap around immediately placed implant
Trial: NCT04803500
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single injection of the solid lipid nanoparticle carrier in the gap around immediately placed implant
Trial: NCT01964404
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsule with no active ingredient
Trial: NCT02881034
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02510118
Drug: mFOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFOX6 regimen is a combination therapy of oxaliplatin (85 mg/m\^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m\^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m\^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (2400 mg/m\^2) via ambulatory pump administered for a period of 46 to 48 hours.
Trial: NCT02510118
Drug: XELOX
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: XELOX is a combination therapy of Oxaliplatin 130mg/ m\^2 d1 Intravenous infusion, every 3 weeks. and Capecitabine 1000mg/m\^2 bid, days 1-14, every 3 weeks
Trial: NCT02194127
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02510118
Drug: Placebo ChangTai Keli
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of dampness stasis type of spleen deficiency will be given placebo ChangTai Keli, twice daily for 26 weeks for lower dosage.
Trial: NCT02510118
Drug: ChangTai Keli
RxNorm normalized name: CALCIUM 0.99 ORAL TABLET [HANTAI 8030 Ca-D3 GOLD]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of dampness stasis type of spleen deficiency will be given placebo ChangTai Keli, twice daily for 26 weeks for lower dosage.
Trial: NCT03059615
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin is an anthracycline antibiotic with antineoplastic activity. Doxorubicin, isolated from the bacterium Streptomyces peucetius var. caesius, is the hydroxylated congener of daunorubicin. Doxorubicin intercalates between base pairs in the DNA helix, thereby preventing DNA replication and ultimately inhibiting protein synthesis.
Trial: NCT00367861
Drug: interruption of Glivec®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: interruption of Glivec®
Trial: NCT02606253
Drug: Chlorothiazide
RxNorm normalized name: Chlorothiazide
DrugBank: Chlorothiazide (DB00880)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorothiazide (Diuril) is an intravenous thiazide diuretic that works in the distal convoluted tubule of the nephron to cause diuresis.
Trial: NCT01455688
Drug: early HAART
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initiation of HAART within 5 days of ICU admission
Trial: NCT01455688
Drug: Late HAART
RxNorm normalized name: porcine heart preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initiation of HAART after ICU discharge
Trial: NCT04243863
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: one dose Part 2: 28 doses (once every 8 hour \[q8h\] dosing for 9 days with a single morning dose on Day 10)
Trial: NCT00464204
Drug: 0.9 % NaCl
RxNorm normalized name: dextrose 10 %-0.9 % NaCl MISCELL LIQUID (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 0.9 % was administered intravenously. NaCl 0.9% rates were not to exceed 50 mL/kg/day on the first day and 25 mL/kg/day from the second to the fourth day, according to patient needs.
Trial: NCT00674050
Drug: Technosphere Insulin (TI) Inhalation Powder
RxNorm normalized name: insulin, regular, human Inhalation Powder [Afrezza]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 U of human insulin. 5 or 10 mg or Technosphere Inhalation Powder, containing 15 0r 30 U of insulin.
Trial: NCT00962832
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was supplied as a sterile liquid solution.
Trial: NCT02014636
Drug: MK-3475
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK 3475 is an intravenously administered 100 mg/ 4mL solution available in the potential dose range of 1 to 10 mg/kg.
Trial: NCT00035282
Drug: Comparator: placebo (unspecified)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03253276
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01806363
Drug: Chlorthalidone 25mg
RxNorm normalized name: CHLORTHALIDONE 25MG TAB
DrugBank: Chlorthalidone (DB00310)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01962571
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03931460
Drug: Medical Abortion
RxNorm normalized name: ABSORPTION BASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical Abortion
Trial: NCT01154374
Drug: MEBO Wound Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application twice daily
Trial: NCT02441283
Drug: ABT-493
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-493 was not administered in this study. This study was a follow-up for participants who received the drug in prior studies.
Trial: NCT02076997
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will receive 5g/m\^2 high dose methotrexate as a 24 hour infusion.~The methotrexate level in the blood will be checked at two times during the 24-infusion. The dose will be reduced based on the level in the blood.
Trial: NCT02774382
Drug: Rectal bacteriotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Already incl. in arm description
Trial: NCT02441283
Drug: ABT-530
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-530 was not administered in this study. This study was a follow-up for participants who received the drug in prior studies.
Trial: NCT01325441
Drug: BBI608
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01664728
Drug: Glucocorticoid
RxNorm normalized name: Glucocorticoid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prednisolone/prednisone 5 mg taken orally twice daily or dexamethasone 0.5 mg taken orally once daily
Trial: NCT00041392
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02348463
Drug: Clindamycin-2-phosphate
RxNorm normalized name: Acanya (benzoyl peroxide 2.5 % / clindamycin-2-phosphate 1.2 % ) Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: how many women will deliver before the 37th week of gestation
Trial: NCT03506763
Drug: Diclofenac oral + Placebo Oral
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac oral + Placebo Oral
Trial: NCT03506763
Drug: Diclofenac oral + scopolamina oral
RxNorm normalized name: diclofenac Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac oral + scopolamina oral
Trial: NCT00988663
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: will give placebo that looks like memantine
Trial: NCT03957564
Drug: Neoadjuvant chemotherapy with PSOX regimen.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resectable gastric or gastro-oesophageal junction cancer patients receiving neoadjuvant chemotherapy with PSOX（Paclitaxel+Oxaliplatin+S1）regimen.~The details are as follows:~Paclitaxel 135mg/m2 d1, Oxaliplatin 85mg/m2 d1, S1 40-60mg/m2 twice daily, d1-14 , 21 days is one cycle.
Trial: NCT04276428
Drug: LY3209590
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC.
Trial: NCT01648582
Drug: Sulfonylureas
RxNorm normalized name: Sulfonylureas
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally at pre-study prescribed dose, and is not being provided as part of the trial.
Trial: NCT00448591
Drug: Taxane-based chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As prescribed
Trial: NCT01871662
Drug: Legalon® SIL (Silibinin)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silibinin 20 mg/Kg/day
Trial: NCT00972673
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: comparator
Trial: NCT00972673
Drug: GW685698X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled steroid
Trial: NCT01844050
Drug: Chinese herbal medicine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: According to the traditional Chinese medicine syndrome of subject to make up a prescription within the 35 kinds of chosen Chinese herbal medicine, and the dosage without limitation.
Trial: NCT01844050
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02229838
Drug: BIBB 1464 MS placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01959672
Drug: Fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01959672
Drug: Leucovorin Calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01160796
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1x14-day course of treatment during 4 cycles
Trial: NCT01160796
Drug: Lcr35®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1x14-day course of treatment during 4 cycles
Trial: NCT00589186
Drug: celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03208244
Drug: Clinically prescribed direct acting antiviral
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCV treatment for 12 weeks
Trial: NCT00609674
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03340376
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin
Trial: NCT01058668
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for three weeks.
Trial: NCT03437265
Drug: PLENVU powder for oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLENVU Dose 1 (1 sachet) and PLENVU Dose 2 (2 sachets)
Trial: NCT00640328
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo
Trial: NCT00252967
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00599079
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Azithromycin Daily Dosage dependent on clinical factos such as age, weight and patient specific health descriptors
Trial: NCT01251107
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 35 mg/2 iv on day 1 during cycles 1 to 4; 25 mg/m2 iv on day 1 during cycles 5 to 8
Trial: NCT01251107
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1250 mg/m2 iv on day 1 during cycles 1 to 4; 650 mg/m2 iv on day 1 during cycles 5 to 8
Trial: NCT01251107
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 25 mg/m2 iv on days 1 and 15 in each cycle
Trial: NCT00137111
Drug: Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See Detailed Description sections for details on treatment interventions.
Trial: NCT00137111
Drug: Methotrexate, Cyclophosphamide, Cytarabine, Etoposide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See Detailed Description sections for details on treatment interventions.
Trial: NCT00137111
Drug: Mercaptopurine, Imatinib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: See Detailed Description sections for details on treatment interventions.
Trial: NCT02526004
Drug: Tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00888862
Drug: Desvenlafaxine Succinate
RxNorm normalized name: Desvenlafaxine Succinate
DrugBank: Desvenlafaxine (DB06700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Desvenlafaxine Succinate, 50-100mg/day for 8 weeks
Trial: NCT03152019
Drug: Protopic® (Tacrolimus) 0.1% ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: About 0,1g of ointment is administered by the patient on nasal mucosa of each nostril twice a day for 6 weeks.
Trial: NCT03152019
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: About 0,1g of ointment is administered by the patient on nasal mucosa of each nostril twice a day for 6 weeks.
Trial: NCT02872207
Drug: BAY 987516 (Y65-122)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 µL in one eye
Trial: NCT02872207
Drug: BAY 987516 (Y65-118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 µL in one eye
Trial: NCT00003331
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003331
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04312048
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one tablet of placebo vaginally 3 hours prior to copper IUD insertion
Trial: NCT00820521
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04687800
Drug: Durezol 0.05% Ophthalmic Emulsion
RxNorm normalized name: Durezol 0.05% Ophthalmic Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy, topical steroid drop
Trial: NCT03861559
Drug: placebo nasal spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intranasal administration
Trial: NCT00782951
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single IV dose of placebo after dental impaction surgery
Trial: NCT01156584
Drug: Toca FC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-6 week cycles of Toca FC. Doses evaluated from 120 mg/kg/day or 300 mg/kg/day. Duration of dosing evaluated: 6 days, 7 days or 14 days.
Trial: NCT00586261
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 30 mg daily for 6 months
Trial: NCT01203384
Drug: CHF5074 1x
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet, 1x, once a day in the morning for 14 days
Trial: NCT01203384
Drug: CHF5074 2x
RxNorm normalized name: Worm Protector 2X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet, 2x, once a day in the morning for 14 days
Trial: NCT01203384
Drug: CHF5074 3x
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet, 3x, once a day in the morning for 14 days
Trial: NCT01203384
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablet, placebo, once a day in the morning for 14 days
Trial: NCT02834468
Drug: DEX Combined With RTX, CSA and IVIG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigators are undertaking a multicenter trial of 100 primary ITP adult patients from 5 medical centers in China. All participants receive dexamethasone (given orally at a dose of 40 mg per day for 4 days), rituximab (given intravenously at a dose of 500mg once), cyclosporin (given orally at a dose of 2.5-3 mg/kg per day for 28 days) and intravenous immunoglobulin (given intravenously at a dose of 5g per month for 6 months) for the treatment of adults newly diagnosed ITP patients.